{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/dental-abscess/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"84291395-fd80-58ef-a144-855cbf9b7b46","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 2f08b67d-49f2-4aa3-a00f-e6843656e422 --><h2>Changes</h2><!-- end field 2f08b67d-49f2-4aa3-a00f-e6843656e422 -->","summary":null,"htmlStringContent":"<!-- begin item 61a3e474-e00c-4bd7-a9a1-623ac9a8b873 --><!-- begin field 356a77cc-d706-4f78-afa1-148723b8be12 --><p><strong>October 2018 </strong>— minor update. Adverse effects updated within prescribing information - metronidazole. </p><p><strong>February 2017 </strong>— reviewed. A literature search was conducted in January 2017 to identify evidence-based guidelines, UK policy, systematic reviews, and key RCTs published since the last revision of the topic. The management section has been restructured. Other changes include removal of: detailed information on analgesia as this is now covered in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/\">Analgesia - mild-to-moderate pain</a> and <a class=\"topic-reference external-reference\" href=\"/topics/nsaids-prescribing-issues/\">NSAIDs - prescribing issues</a>; Clindamycin as a first-line option for antibiotic treatment in primary care; detailed information on dental service provision and dental treatments.</p><!-- end field 356a77cc-d706-4f78-afa1-148723b8be12 --><!-- end item 61a3e474-e00c-4bd7-a9a1-623ac9a8b873 -->","topic":{"id":"d9ce8bcf-6a30-56c3-9028-f291f9b80333","topicId":"7e8f6d78-0b6f-4813-baa8-3184010dd768","topicName":"Dental abscess","slug":"dental-abscess","lastRevised":"Last revised in October 2018","chapters":[{"id":"82801101-5e68-547d-8c3c-4ad6ec3b91b9","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"92e4cbdc-7fa7-574b-bb17-97199587fe2d","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"e4034c8e-5cd0-5dc4-ba1d-f3ca1fe09c21","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"84291395-fd80-58ef-a144-855cbf9b7b46","slug":"changes","fullItemName":"Changes"},{"id":"07b47e29-f600-5771-917c-4d6cd9135ed2","slug":"update","fullItemName":"Update"}]},{"id":"e967b353-dcf8-5e71-a9b0-95ca162918b8","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"244fc23b-f275-5565-b50c-dca750baa8d9","slug":"goals","fullItemName":"Goals"},{"id":"1eb55d27-8795-5d81-8b81-4b4b6b7efa18","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"2423d7f3-a323-50a3-8bbd-9664897bccd4","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"f5780547-92b5-5ede-a620-c7cf34a41b3b","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"e9cfdeb1-ec38-5e0d-b03e-0acd118058b8","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"fa0115e4-0051-5374-8fae-1e1fbec27b97","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"5f20011b-3e94-5351-a2a6-2a9565c42d7a","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"69b7a1cd-7d22-52ab-b602-3a0c4bfbb4d4","slug":"definition","fullItemName":"Definition"},{"id":"617d13f2-34cd-5fd2-8869-198c3a3d5f06","slug":"causes","fullItemName":"Causes"},{"id":"777f9b6b-175c-5308-bba6-916d89e075b3","slug":"prevalence","fullItemName":"Prevalence"},{"id":"cf5def0d-1ffd-5d57-b788-273fc8248d5c","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"735fc661-47ce-5a94-a29f-f0076c17ce88","slug":"complications","fullItemName":"Complications"}]},{"id":"df647f07-2727-5ac9-b87c-5adcdcf79bd6","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"b2a41850-a8dc-5b90-a7c5-4f2216c54cd2","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"d97daa33-59c0-5607-a1fe-03238b7b333f","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"6b0a689b-1ec7-5794-a5f0-b4efc84acfd2","fullItemName":"Management","slug":"management","subChapters":[{"id":"e6487762-ae28-5710-865a-01603c95176a","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"86cee72a-afc7-5150-92f0-6ff0e90b0172","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"a9ed2df0-8168-51d7-b8e8-f5bb7c662d36","slug":"analgesics","fullItemName":"Analgesics"},{"id":"c8a5d71d-6f87-5315-aa1f-59791511dafe","slug":"amoxicillin","fullItemName":"Amoxicillin"},{"id":"9bd34406-b8a3-5ab1-8a5d-3bd78925ef32","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"03d761c0-a760-5547-8910-97a65535bf94","slug":"metronidazole","fullItemName":"Metronidazole"},{"id":"91946ef3-8703-52eb-ba0a-b9cabca622e5","slug":"phenoxymethylpenicillin","fullItemName":"Phenoxymethylpenicillin"}]},{"id":"9c1469e7-dbca-5eaa-b2cd-29e127addf9a","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"aac7c7e4-eb79-5922-8ea7-3250adfae6b3","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"5aabd034-b3df-5bf4-93c1-30787cb35e17","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"6420441b-a18d-5bdb-a114-17409f623a23","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"65e26e16-4508-5e81-a8bf-307836e310cd","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"0aba46be-7078-5b8a-8557-56574cc69291","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"2d089d7b-e753-518e-95f6-04243be55427","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"f724f89d-9d85-5d8b-9675-d551cbf4aa5e","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"e4034c8e-5cd0-5dc4-ba1d-f3ca1fe09c21","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"387593da-9811-5859-a873-77ec7170b871","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field 26f3d933-1e69-445a-95dc-659eae2c967e --><h3>Previous changes</h3><!-- end field 26f3d933-1e69-445a-95dc-659eae2c967e -->","summary":null,"htmlStringContent":"<!-- begin item cadeb5a9-a3c3-4ba9-a2c9-7d393b233be7 --><!-- begin field 5521a9a9-d9f3-4b11-bdc6-5511a89de44c --><p><strong>July 2015</strong> — minor update. The information on the concurrent use of clarithromycin with statins has been clarified.</p><p><strong>April 2015</strong> — minor update. The prescribing information on the use of analgesics in pregnancy and breastfeeding has been removed and replaced with a link to the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/\">Analgesia - mild-to-moderate pain</a>.</p><p><strong>July 2014</strong> — minor update. Update to prescribing information to reflect the fact that there are reports of raised INRs and increased bleeding with the concomitant use of clindamycin and vitamin K antagonists.</p><p><strong>June 2014</strong> — minor update. Update to the text to reflect the fact that tramadol has been reclassified to a Schedule 3 controlled drug.</p><p><strong>January 2014</strong> — minor update. The text regarding the use of codeine during breastfeeding has been updated to reflect new guidance from the Medicines and Healthcare products Regulatory Agency (MHRA). Codeine is no longer recommended for breastfeeding mothers, and tramadol or dihydrocodeine are preferred alternatives.</p><p><strong>July 2013</strong> — minor update. Update to the text to reflect recent advice from the MHRA regarding diclofenac.</p><p><strong>February 2013</strong> — minor update. The 2013 QIPP options for local implementation have been added to this topic.</p><p><strong>January 2013</strong> — minor update. Change to the text to reflect updated advice from the Health Protection Agency and British Infection Association regarding the choice of antibiotic for treating a dental abscess.</p><p><strong>October 2012</strong> — minor update. The 2012 QIPP options for local implementation have been added to this topic.</p><p><strong>September 2012</strong> — reviewed. A literature search was conducted in September 2012 to identify evidence-based guidelines, UK policy, systematic reviews, and key RCTs published since the last revision of the topic. No changes to clinical recommendations have been made.</p><p><strong>May 2011</strong> — minor update. The 2010/2011 QIPP options for local implementation have been added to this topic. Issued in June 2011.</p><p><strong>February 2011</strong> — topic structure revised to ensure consistency across CKS topics — no changes to clinical recommendations have been made.</p><p><strong>June 2010</strong> — minor update. In people at risk of cardiovascular adverse events, ibuprofen up to 1200 mg per day or naproxen up to 1000 mg per day are recommended as first-line NSAIDs. Issued in July 2010.</p><p><strong>October 2007 to January 2008 </strong>— converted from CKS guidance to CKS topic structure. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence. There are no major changes to the recommendations.</p><p><strong>October 2006 </strong>— minor update. Analgesia prescriptions updated because new doses of ibuprofen for children are recommend by the British National Formulary. Issued in October 2006.</p><p><strong>October 2005 </strong>— minor technical update. Issued in November 2005.</p><p><strong>June 2004 </strong>— written. Validated in September 2004 and issued in November 2004.</p><!-- end field 5521a9a9-d9f3-4b11-bdc6-5511a89de44c --><!-- end item cadeb5a9-a3c3-4ba9-a2c9-7d393b233be7 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}